A clinical and metabolic study of masculinizing arrhenoblastoma.
D015065:17-Hydroxycorticosteroids / Q000652:urine; D015068:17-Ketosteroids / Q000652:urine; D000311:Adrenal Glands / Q000187:drug effects; D000324:Adrenocorticotropic Hormone / Q000378:metabolism; D000328:Adult; D001831:Body Temperature; D003907:Dexamethasone / Q000494:pharmacology; D004967:Estrogens / Q000652:urine; D005260:Female; D005640:Follicle Stimulating Hormone / Q000652:urine; D006628:Hirsutism / Q000150:complications; D006801:Humans; D007621:Karyotyping; D010051:Ovarian Neoplasms / Q000150:complications* / Q000378:metabolism* / Q000473:pathology; D011276:Pregnanediol / Q000652:urine; D011279:Pregnanetriol / Q000652:urine; D018310:Sertoli-Leydig Cell Tumor / Q000150:complications* / Q000378:metabolism* / Q000473:pathology; D013739:Testosterone / Q000378:metabolism; D014770:Virilism / Q000150:complications* / Q000378:metabolism*
D015065:17-Hydroxycorticosteroids; D015068:17-Ketosteroids; D004967:Estrogens; D011279:Pregnanetriol; D013739:Testosterone; D003907:Dexamethasone; D000324:Adrenocorticotropic Hormone; D005640:Follicle Stimulating Hormone; D011276:Pregnanediol